Article Text

Download PDFPDF
What is the place in therapy for nirmatrelvir/ritonavir?

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @DrToddLee, @jpogue1, @ErinMcCreary, @ASPphysician

  • Contributors All authors participated in the conceptualisation, drafting and revisions of the manuscript and have given permission to submit for publication. TCL, as corresponding author, is responsible for the overall content as guarantor.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests TCL reports receiving research salary support from Fonds de Recherche du Québec–Santé and peer-reviewed operating grants for COVID-19-related research from the Canadian Institutes of Health Research and being an investigator for several investigator-initiated trials involving outpatients with Covid-19. JMP discloses serving as a consultant to Merck, Shionogi and Roche. EKM discloses serving as a consultant to Shionogi and is the Director of infectious diseases improvement and clinical research innovation at UPMC. In this role, EKM oversaw clinical trials involving use of sotrovimab (donated by GSK) and evaluation of tixagevimab–cilgavimab in outpatients (funded by AstraZeneca). She does not receive salary support or funding for her involvement in these trials. AMM has no competing interest to declare.

  • Provenance and peer review Not commissioned; externally peer reviewed.